• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Government proposes rule changes on human research

Government proposes rule changes on human research

July 25, 2011
CenterWatch Staff

The government is proposing changes in the rules covering research involving human subjects, an effort officials say would strengthen protections while reducing red tape that can impede studies, according to The New York Times.

The officials said the changes were needed to deal with a vastly altered research climate, whose new features include genomics studies using patients’ DNA samples, the use of the Internet and a growing reliance on studies that take place at many sites at once.

“These are the first substantial changes that have been made to the rules governing human subjects in decades, so this is really quite a historic moment,” Kathy Hudson, a deputy director of the National Institutes of Health told The Times.

The changes would be in the rules that cover topics like the informed consent that research participants must provide and the IRBs that oversee research at universities and hospitals. Initially drawn up by the Department of Health and Human Services in the 1970s and ’80s, the system was adopted by 14 other federal agencies and departments in 1991 and became known as the Common Rule.

The process is still at an early stage. The government has described possible changes and asked for public comment over the next 60 days; after that, specific rules will be formulated and again sent out for comment.

The government said its proposal was consistent with President Obama’s executive order in January calling on agencies to weed out unnecessary regulations. But some of the proposed changes would add regulation.

One change would expand the rules’ coverage to all studies conducted at institutions that receive money from any of the 15 federal agencies that have adopted the Common Rule. For example, if a university gets financing from the National Institutes of Health, then even a study at that university paid for by a drug company would be covered by the rules.

While that would encompass more medical research, it was not clear whether trials financed by drug companies and conducted at individual physicians’ offices would be covered.

Another proposed change would allow a single IRB to oversee studies that take place at multiple sites. Now, the IRB at each location generally must endorse a trial, which can lead to long delays. Federal officials said besides eliminating redundancy and delays, having a single reviewer that is truly accountable for its decisions might actually strengthen oversight.

Another possible change would be that donors of blood, DNA or tissue samples would be asked to give consent before those samples could be used in subsequent research. If the identity of the donor cannot be determined, samples can often be used for further research without permission. But Hudson, of the health institutes, said with modern DNA sequencing, biological specimens are “inherently identifiable.” So the proposal would make consent required.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing